RxDoctor Payments Data

Melissa Wells, NP

Nurse Practitioner · Oak Ridge, TNNPI 1295346195

Payments from drug & device makers

$1,900in general payments, 2019–2025

Across 93 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$698
  • Bayer$329
  • OPKO Pharmaceuticals, LLC$180
  • Travere Therapeutics, Inc.$163
  • Calliditas Therapeutics US Inc.$117
  • Boehringer Ingelheim$107
  • plus $307 from 7 others

What the payments were for

  • Food & beverage$1,88299%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,900 in reported general payments places this provider in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$69,328
Medicare patients
408
Services billed
1,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol72$77,307
RayaldeeCalcifediol35$52,963
KerendiaFinerenone21$23,185
LokelmaSodium Zirconium Cyclosilicate19$20,052
VeltassaPatiromer Calcium Sorbitex16$8,099
Calcitriol361$4,441
Bumetanide75$2,815
Torsemide185$2,620
Chlorthalidone142$2,121
Eplerenone20$1,876
Hydralazine Hcl94$1,350
ProsolParenteral Amino Acid 20% No.111$1,330
Potassium Citrate ErPotassium Citrate11$1,275
Losartan Potassium154$1,168
Nifedipine ErNifedipine34$893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$698$97,36091 claims
OPKO Pharmaceuticals, LLCRayaldee$180$52,96335 claims
BayerKerendia$329$23,18521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Oak Ridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →